NetworkNewsBreaks – Endonovo Therapeutics, Inc.
Post# of 7
(Total Views: 959)
Posted On: 01/30/2020 3:38:20 PM
NetworkNewsBreaks – Endonovo Therapeutics, Inc. (ENDV) Receives SofPulse(R) Orders From Multiple Plastic Surgery Centers
Endonovo Therapeutics (OTCQB: ENDV) today announced that it has secured sales of SofPulse(R), the company’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema, to multiple plastic surgery centers. “SofPulse(R) main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures. With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse(R) demonstrates different applications for its use,” Endonovo Therapeutics CEO Alan Collier stated in the news release. “We are quickly becoming the go to pain and edema reduction option for many out-patient surgical procedures performed at ASC’s throughout the US. These centers provide patients with cosmetic and reconstructive procedures resulting in a need for postoperative pain management. Many of the plastic surgery centers have state-of-the-art surgical suites and recovery rooms equipped to hospital standards and we continue working with these centers and completing evaluations. Although in the nascent stages of expanding into fully certified office-based surgery centers, we recognize the large and growing market size allowing us to be well poised to capitalize on this opportunity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV) today announced that it has secured sales of SofPulse(R), the company’s FDA-Cleared, non-invasive device utilized for the reduction of postoperative pain and edema, to multiple plastic surgery centers. “SofPulse(R) main distribution model is marketing to major hospitals throughout the US and is beginning to be viewed as the standard of care for postoperative pain and edema reduction for numerous inpatient hospital procedures. With the expansion of our customer base and recent orders from numerous plastic surgery centers, SofPulse(R) demonstrates different applications for its use,” Endonovo Therapeutics CEO Alan Collier stated in the news release. “We are quickly becoming the go to pain and edema reduction option for many out-patient surgical procedures performed at ASC’s throughout the US. These centers provide patients with cosmetic and reconstructive procedures resulting in a need for postoperative pain management. Many of the plastic surgery centers have state-of-the-art surgical suites and recovery rooms equipped to hospital standards and we continue working with these centers and completing evaluations. Although in the nascent stages of expanding into fully certified office-based surgery centers, we recognize the large and growing market size allowing us to be well poised to capitalize on this opportunity.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)